Rockwell Medical Inc.
2.00
-0.01 (-0.50%)
At close: Jan 14, 2025, 3:59 PM
2.07
3.76%
After-hours Jan 14, 2025, 05:33 PM EST
undefined%
Bid 1.99
Market Cap 64.48M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.04
PE Ratio (ttm) -49.87
Forward PE n/a
Analyst Buy
Ask 2.07
Volume 241,702
Avg. Volume (20D) 726,406
Open 2.06
Previous Close 2.01
Day's Range 1.98 - 2.06
52-Week Range 1.16 - 5.15
Beta undefined

About RMTI

Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stor...

Sector Healthcare
IPO Date Jan 27, 1998
Employees 237
Stock Exchange NASDAQ
Ticker Symbol RMTI

Analyst Forecast

According to 2 analyst ratings, the average rating for RMTI stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 200.75% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Rockwell Medical Inc. is scheduled to release its earnings on Mar 20, 2025, before market opens.
Analysts project revenue of $25.16M, reflecting a 13.88% YoY growth and earnings per share of 0.01, making a -50.00% decrease YoY.
4 weeks ago · Source
+10.45%
Rockwell Medical shares are trading higher after t... Unlock content with Pro Subscription
2 months ago · Source
-39.14%
Rockwell Medical shares are trading lower. The company reported Q3 financial results.